samples by standard procedures after isolation of total leukocytes following red-cell lysis. The JAK2 V617F mutation was detected using a tetra-primer amplification refractory mutation system (ARMS) polymerase chain reaction (PCR) assay with a sensitivity of 1%. 7 The observed incidence of JAK2 V617F mutated cases was compared with the incidence of 5% using the Clopper-Pearson exact test. Statistical analysis was performed using STATA, version SE/10 (STATA Corp, College Station, TX). Significance was defined as P-value o0.05; P-values were two-tailed. 8 The study was approved by the internal review boards from all the participating institutes and written informed consent was obtained from all patients according to the Declaration of Helsinki.
Corticosteroid therapy has been a long-standing component in the treatment of multiple myeloma, in which it is believed to reduce monoclonal protein levels and increase chemotherapeutic response. Earlier, high doses of dexamethasone were empirically chosen, given the paucity of specific trial data to guide optimal dosing. However, with the advent of agents with increasing activity in multiple myeloma, such as lenalidomide and bortezomib, the necessity for high-dose dexamethasone has been questioned. It is noted that in the Eastern Cooperative Oncology Group trial E4A03, in which participants were randomized to receive either low-or high-dose dexamethasone in combination with lenalidomide, 1 it was the low-dose dexamethasone regimen that was associated with significantly better 1-and 2-year overall survival rates (especially among patients under 65 years of age), as well as significantly lower toxicity (major grade 3 or higher toxicities, including deep vein thrombosis, pulmonary embolism and infections) despite the high-dose regimen producing higher response rates. However, it was not clear from this trial whether the dexamethasone doses had a differential impact on adrenal suppression and whether this played any role in the observed outcomes.
High-dose dexamethasone-based regimens for the treatment of myeloma have most frequently involved the administration of oral dexamethasone 40 mg on days 1-4, 9-12 and 17-20 of each 28-day cycle; low-dose regimens (as in Eastern Cooperative Oncology Group E4A03) have utilized oral dexamethasone 40 mg on days 1, 8, 15 and 22 of each 28-day cycle. With physiologic corticosteroid replacement estimated to be approximately 0.5-0.75 mg/day of dexamethasone, the high-dose regimen translates into more than 30-fold, and low-dose into more than 10-fold, of the normal physiologic levels. Some authors suggest that any patient who has received an equivalent of 20-30 mg/day of prednisolone (approximately equivalent to 0.5-0.75 mg/day of dexamethasone) for more than 5 days may be at risk of adrenal suppression, 2 whereas others contend that several weeks of exogenous glucocorticoid administration at replacement dosing are required for the development of adrenal insufficiency.
3 Further, there is significant individual variability in susceptibility to suppression of the hypothalamic-pituitaryadrenal axis by exogenous glucocorticoids, making it difficult to reliably predict the occurrence of adrenal suppression from the dose and duration of glucocorticoid used alone. 4 Thus, it is of interest to determine whether the difference in clinically favorable outcomes found with low-dose compared with highdose dexamethasone regimens was associated with differences in adrenal suppression.
From our myeloma database, we were able to identify 11 patients who had received high-dose dexamethasone, 34 patients who had received low-dose dexamethasone and who also had early morning 0800-hour serum cortisol levels determined both at baseline and again at 3 months after initiation of their dexamethasone-based chemotherapeutic treatment regimens. The 3-month 0800-hour serum cortisol samples were routinely obtained at the end of a weekly treatment cycle (that is, 4-7 days after the last dose of dexamethasone). Median ages were 56 years (range 44-70) in the high-dose and 67 years (range 50-89) in the low-dose dexamethasone groups, respectively. Chi-square and Fisher's exact tests were used to compare differences among the patient groups for nominal variables, and the Wilcoxon rank-sum test was used for continuous variables (Table 1) . At baseline, the high-and low-dose dexamethasone groups showed no significant differences in their 0800-hour serum cortisol levels. At 3 months, however, 72.7% of subjects in the high-dose dexamethasone group had a decline (from baseline) in 0800-hour cortisol levels, compared with 32.4% of subjects in the low-dose dexamethasone group (P ¼ 0.03). The proportion of patients with a 3-month 0800-hour serum cortisol level below 3 mcg/100 ml (a level considered to be presumptive evidence of adrenal suppression) 5, 6 was significantly higher in patients receiving high-dose dexamethasone compared with participants receiving low-dose dexamethasone (45.5 vs 8.8%, P ¼ 0.01). Similarly, the proportion of patients with a 3-month 0800-hour serum cortisol level below 10 mcg/100 ml (a level considered to be 'suggestive' of adrenal suppression) 7 was higher in the high-dose group (63.6 vs 32.4%, P ¼ 0.09), although this did not reach statistical significance. Overall, patients in the high-dose group experienced a mean decline of 6.4 mcg/100 ml in their 0800-hour serum cortisol levels after 3 months (95% confidence interval: À10.7, À2.1), whereas those in the low-dose group showed no significant change (95% confidence interval: À0.2, 4.3).
These data suggest that high-dose dexamethasone regimens may induce substantial adrenal suppression in a significant proportion of patients. Further, approximately one-third of the patients receiving low-dose dexamethasone, the current dexamethasone regimen of choice, had 0800-hour cortisol levels below 10 mcg/100 ml, including approximately 9% with cortisol levels o3 mcg/100 ml, after 3 months of treatment, suggesting that a proportion of patients receiving even low-dose dexamethasone is at risk of developing adrenal insufficiency.
We acknowledge that there are several limitations to our study. First, this is a retrospective study carried out on stored serum and hence endogenous cortisol secretion was assessed by determination of 0800-hour serum cortisol levels rather than by a provocative stimulation test, which may have provided more objective results. Second, whereas the 3-month samples were routinely obtained at the end of a weekly treatment cycle in which dexamethasone is ingested on the first day of each week, it is possible that for some participants this may not have been the case, which might lead to erroneous assessments of adrenal suppression. Despite these limitations, we hope that the data presented here will alert clinicians to consider evaluating adrenal function in patients with multiple myeloma who receive dexamethasone-based chemotherapeutic regimens. Finally, additional prospective studies are needed to determine the impact of corticosteroid-induced adrenal insufficiency on important treatment outcomes, such as symptom relief and disease prognosis. Baseline 0800-hour serum cortisol (mcg/100 ml) 12.9 10.9 NS 3-month 0800-hour serum cortisol (mcg/100 ml) 6.5 12.9 o0.01 Change in 0800-hour serum cortisol at 3 months (mcg/100 ml) À6.4 2.0 o0.01 Proportion with decline in 0800-hour serum cortisol at 3 months 8/11 (72.7%) 11/34 (32.4%) 0.03 Proportion with 0800-hour serum cortisol o3 mcg/100 ml at 3 months 5/11 (45.5%) 3/34 (8.8%) 0.01 Proportion with 0800-hour serum cortisol o10 mcg/100 ml at 3 months 7/11 (63.6%) 11/34 (32.4%) 0.09
Abbreviation: NS, not significant.
Letters to the Editor
Genomic alterations have increasingly gained importance as prognostic markers in B-cell chronic lymphocytic leukemia (CLL). The identification of genetic alterations of prognostic importance in CLL is accomplished currently using commercially available fluorescence in situ hybridization (FISH) panels that can detect the most common recurrent aberrations in CLL, involving chromosomes 11q, 13q, 14q, 17p and whole chromosome 12.
1-4
Although the use of FISH analysis has improved the detection rate of genomic alterations in CLL from B50% using conventional cytogenetics to 480%, 5 there is a need for improved methods to identify prognostic markers that can aid in the risk-stratification of these patients. The identification of high-risk patients is essential for treatment planning and is of particular importance in earlystage, asymptomatic CLL patients, for whom rapid disease progression and a poor prognosis can be predicted by the presence of specific genomic abnormalities such as 11q and 17p deletions. [6] [7] [8] Recently, array comparative genomic hybridization (array CGH) has been gaining acceptance as a diagnostic tool that can also be applied to detect genomic gains and losses of prognostic importance in CLL, because of the advantages afforded by simultaneous genome-wide and locus-specific assessment of the leukemia with a single assay.
9-14
Array CGH is well suited for the identification of genomic alterations of prognostic importance in CLL, because the most common and important aberrations are comprised of genomic losses and gains, whereas chromosomal translocations are relatively rare. Although translocations do occur in CLL, their prognostic significance is currently controversial. In a number of recent studies evaluating the use of array CGH as a clinical tool for genomic alteration detection in CLL, array CGH results have exhibited a high concordance with parallel FISH studies, except when FISH aberrations are present in less than B25-30% of the cells.
9-14 In a recent report from our laboratory, we analyzed 174 cases of CLL by bacterial artificial chromosome (BAC)-based array CGH and found that we could identify correctly the aberrations identified by FISH 96% of the time. 12 The discordant results were because of small clonal cell populations that comprised o25-30% of the total sample. Interestingly, two CLL cases with cryptic (B1 Mb) 13q14 deletions detected by array CGH were missed by both of the 13q14 region FISH probes used in this study. These findings suggested that array CGH had advantages over FISH for the identification of certain types of genomic alterations in CLL. In this study, we present four additional CLL cases with atypical 11q deletions, including two cases that were not identified properly by a commercially available five-probe FISH panel that also included an 11q22.3 Vysis LSI ATM probe (Abbott Molecular, Des Plaines, IL, USA). This study is also the first to report CLL cases with large 11q deletions that do not include the ATM (Ataxia telangiectasia mutated) gene, suggesting that additional genes in this region may be important for the pathogenesis of CLL. Bacterial artificial chromosome array-based array GCH was used to detect recurrent genomic alterations in 190 cases of CLL using a clinically validated array designed to interrogate all known CLL prognostic loci.
11 This array contains 179 CLL prognostic marker probes along with a backbone of 914 FISH-mapped linearly distributed clones for wholegenome coverage at an average resolution of B2.5 Mb. This analysis identified 22 CLL cases with 11q deletions, with 20 cases that included the ATM gene in the deleted region. However, four of the CLL cases showed atypical 11q deletions, with two cases (Cases 1 and 2) exhibiting a centromeric breakpoint just proximal to the ATM locus, and two cases (Cases 3 and 4) exhibiting proximal breakpoints telomeric to the ATM gene (Figure 1) . Oligonucleotide-based array CGH analysis (Agilent Technologies 44 K or 105 K arrays, Santa Clara, CA, USA) was also used to confirm the 11q deletions and to map the deletion breakpoints in 15 of the 22 chromosome 11q deletion cases identified by the BAC array. This analysis identified a minimal region of deletion on 11q of B2.94 Mb (Table 1) .
Bacterial artificial chromosome array CGH analysis of Case 1 revealed a 2.4 Mb deletion of 13q and an B11 Mb deletion of 11q23 involving 19 clones at linear positions 107.57-118.29
